





























































What is claimed:





















1. A compound selected from the group consisting of












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Substitute Sheet (Rule 26)














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

2. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

3. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

4. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

5. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

6. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

7. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

8. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

9. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

10. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

11. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

12. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

13. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

14. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

15. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

16. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

17. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

18. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

19. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

20. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

21. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

22. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

23. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

24. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

25. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

26. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

27. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

28. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

29. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

30. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

31. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

32. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

33. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

34. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

35. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

36. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

37. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

38. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

39. A compound of claim 1 having the formula:




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

40. A compound of claim 1 having the formula:



or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

41. A compound of claim 1 having the formula:



or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or ester thereof.

42. A compound of claim 1, in isolated and purified form.

43. A pharmaceutical composition comprising an effective amount of at least one compound of claim 1 and a pharmaceutically effective carrier.

44. A method of inhibiting aspartyl protease comprising administering to a patient in need of such treatment an effective amount of at least one compound of claim 1.

45. A method of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes comprising administering to a patient in need of such treatment an effective amount of at least one compound of claim 1.

46. The method of claim 45 wherein a cognitive or neurodegenerative disease is treated.

47. The method of claim 46 wherein Alzheimer's disease is treated.

48. A pharmaceutical composition comprising an effective amount of at least one compound of claim 1, and an effective amount of a cholinesterase inhibitor or a muscarinic m_1 agonist or m_2 antagonist in a pharmaceutically effective carrier.

49. A method of treating a cognitive or neurodegenerative disease comprising administering to a patient in need of such treatment an effective amount of at least one compound of claim 1 in combination with an effective amount of a cholinesterase inhibitor.

50. The method of claim 49 wherein Alzheimer's disease is treated.

51. A method of treating a cognitive or neurodegenerative disease comprising administering to a patient in need of such treatment an effective amount of at least one compound of claim 1 in combination with an effective amount of a N-methyl-D-aspartate receptor antagonist, gamma secretase inhibitor, an HMG-CoA reductase inhibitor or non-steroidal anti-inflammatory agent.

52. The method of claim 51 wherein Alzheimer's disease is treated.

53. The method of claim 51 wherein said HMG-CoA reductase inhibitor is atorvastatin, lovastatin, simvistatin, pravastatin, fluvastatin or rosuvastatin.


54. The method of claim 51 wherein said non-steroidal anti-inflammatory agent is ibuprofen, relafen or naproxen.

55. The method of claim 51 wherein said N-methyl-D-aspartate receptor antagonist is memantine.

56. A pharmaceutical composition comprising an effective amount of at least one compound of claim 1, and an effective amount of a N-methyl-D-aspartate receptor antagonist, gamma secretase inhibitor; an HMG-CoA reductase inhibitor or a non-steroidal anti-inflammatory agent.

57. A method of treating a cognitive or neurodegenerative disease comprising administering to a patient in need of such treatment an effective amount of at least one compound of claim 1 in combination with an effective amount of one or more compounds selected from the group consisting of a cholinesterase inhibitor, muscarinic m_1 agonist or m_2 antagonist, N-methyl-D-aspartate receptor antagonist, gamma secretase inhibitor, an HMG-CoA reductase inhibitor and non-steroidal anti-inflammatory agent.


58. A process for preparing a compound of Formula B:



B

the process comprising the steps of:

(a) reacting the compound of Formula A:



A

with R^3-X in a solvent in the presence of a base, optionally with $ZnCl_2$, and a palladium/phosphine catalyst at about -78 to 0°C, wherein X is Cl, Br, I, or OTf;

(b) raising the temperature of the reaction mixture to about 50-100°C; and

(c) treating with an acid, to provide the compound of Formula B,

wherein

W is –C(O)– or –$S(O)_2$–;

R^1 is selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl;

R^3 is selected from the group consisting of aryl, heteroaryl and alkenyl; and

R^6 and R^7 are selected from the group consisting of H, aryl, heteroaryl, alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, arylalkyl and heteroarylalkyl.

59. The process of claim 58, wherein said solvent is an ether, hydrocarbon, amide or sulfoxide.

60. The process of claim 58, wherein said palladium/phosphine catalyst is $Pd_2(dba)_3$, $PdCl_2$, $PdOAc_2$ / Davephos, Q-phos, Bis(2-diphenylphosphinophenyl) ether, 9,9-Dimethyl-4,5-bis(diphenylphoshino)xanthene, 2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl, 1,1'-Bis(diphenylphosphino)ferrocene, 1,4-Bis(diphenylphosphino)butane, 1-dicyclohexylphosphino-2-di-tert-butylphosphinoethylferrocene (CyPF-tBu), DPEphos, Xantphos, DPPF, triphenylphosphine, 1,3-bis(diphenylphospino)propane, 1,2-bis(diphenylphosphino)ethane, 1,4-bis(diphenylphosphino)butane, tri-tertbutylphosphine, tricyclohexylphosphine, 1,1'-bis(di-tert-butylphosphino)ferrocene, 1,1'-bis(di-isopropylphosphino)ferrocene, tri-o-tolylphosphine, 1,1'-bis(diphenylphosphino)ferrocene, di-tert-butylphenylphosphine, 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, FibreCat, or XPhos.

61. The process of claim 58, wherein said acid is selected from the group consisting of trifluoroacetic acid, hydrochloric acid and hydrobromic acid.



62. The process of claim 58, wherein said X is bromide.



5




63. The process of claim 1, wherein said base is selected from the group consisting of LIHMDS, LDA, BuLi, s-BuLi and tert-Butyllithium.




CLAIMS




1. A compound, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein said compound is selected from the group consisting of:




Str #	Structure
1945	
2118	




Str #	Structure
2174	
2438	




Str #	Structure
2522	
2723	
2759	


Str #	Structure
2782	
2833	
2937	

Str #	Structure
2983	 ,
3206	 ,
3306	 ,

Str #	Structure
3383	 ,
3659	 ,
3783	 ,

Str #	Structure
3888	 ,
3963	 ,
3986	 ,


Str #	Structure
4088	 ,
4115	 ,
4308	 , and

Str #	Structure
4328	


2. A compound according to claim 1, or a tautomer thereof, wherein said compound or said tautomer is in the form of a pharmaceutically acceptable salt, wherein said salt is selected from: acetate, adipate, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate and hexanoate.

3. A compound according to claim 1, or a tautomer thereof, wherein said compound or said tautomer is in the form of a pharmaceutically acceptable salt, wherein said salt is selected from: hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, methyl sulfate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, sulfonates, tartarate, thiocyanate, tosylate and undecanoate.


4. A compound according to claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein said compound is:

Str #	Structure
2782	


5. A compound according to claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein said compound is:

Str #	Structure
3306	

6. A compound according to claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein said compound is:


Str #	Structure
3383	

7. A compound according to claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein said compound is:


Str #	Structure
3659	

8. A compound according to claim 7, or a tautomer thereof, wherein said compound or said tautomer is in the form of a pharmaceutically acceptable salt, wherein said salt is a tosylate salt or a hydrochloride salt.


9. A compound according to claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein said compound is:

Str #	Structure
3783	

10. A compound according to claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein said compound is:


Str #	Structure
3963	

11. A compound according to claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein said compound is:

Str #	Structure
3986	

12. A compound according to claim 11, or a tautomer thereof, wherein said compound or said tautomer is in the form of a pharmaceutically acceptable salt, wherein said salt is a tosylate salt or a hydrochloride salt.

13. A compound according to claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein said compound is:

Str #	Structure
4308	

14. A pharmaceutical composition comprising: a compound according to any one of claims 1 to 13, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer; and a pharmaceutically acceptable carrier.

15. A pharmaceutical composition according to claim 14, further comprising at least one additional active agent selected from: a cholinesterase inhibitor; a muscarinic m_1 agonist; a muscarinic m_2 antagonist; a N-methyl-D-aspartate receptor antagonist; a beta secretase inhibitor other than a compound of claim 1; a gamma secretase inhibitor; an HMG-CoA reductase inhibitor; a cholesterol absorption inhibitor; a non-steroidal anti-inflammatory agent; an anti-amyloid antibody; vitamin E; a nicotinic acetylcholine receptor agonist; a CB1 receptor inverse agonist; a CB1 receptor antagonist; an antibiotic; a growth hormone secretagogue; a histamine H3 antagonist; an AMPA agonist; a PDE4 inhibitor; a $GABA_A$ inverse agonist; an inhibitor of amyloid aggregation; a glycogen synthase kinase beta inhibitor; and a promoter of alpha secretase activity.

16. A pharmaceutical composition according to claim 15, wherein said at least one additional active agent is a cholinesterase inhibitor selected from tacrine, donepezil, rivastigmine, galantamine, pyridostigmine and neostigmine.

17. A pharmaceutical composition according to claim 16, wherein said cholinesterase inhibitor is selected from tacrine, donepezil, rivastigmine and galantamine.

18. A pharmaceutical composition according to claim 15, wherein said at least one additional active agent is selected from a muscarinic m_1 agonist and a muscarinic m_2 antagonist.

19. A pharmaceutical composition according to claim 15, wherein said at least one additional active agent is an N-methyl-D-aspartate receptor antagonist.

20. A pharmaceutical composition according to claim 19, wherein said N-methyl-D-aspartate receptor antagonist is memantine.

21. A pharmaceutical composition according to claim 15, wherein said at least one additional active agent is a gamma secretase inhibitor.

22. A pharmaceutical composition according to claim 15, wherein said at least one additional active agent is at least one agent selected from an HMG-CoA reductase inhibitor and a cholesterol absorption inhibitor.

23. A pharmaceutical composition according to claim 22, wherein said HMG-CoA reductase inhibitor is selected from atorvastatin, lovastatin, simvistatin, pravastatin, fluvastatin and rosuvastatin.

24. A pharmaceutical composition according to claim 22, wherein said cholesterol absorption inhibitor is ezetimibe.

25. A pharmaceutical composition according to claim 15, wherein said at least one additional active agent is at least one non-steroidal anti-inflammatory agent.

26. A pharmaceutical composition according to claim 25, wherein said at least one non-steroidal anti-inflammatory agent is selected from ibuprofen, relafen and naproxen.

27. Use of a compound for the manufacture of a medicament for treating a cardiovascular disease, a cognitive or neurodegenerative disease, a fungal infection, or a protozoal infection in a patient, wherein said compound is a compound according to any one of claims 1 to 13, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

28. Use of a compound for the manufacture of a medicament for treating a cognitive or neurodegenerative disease in a patient, wherein said compound is a compound according to any one of claims 1 to 13, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

29. The use according to claim 28, wherein said cognitive or neurodegenerative disease is Alzheimer's disease.